KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Cash (2016 - 2025)

TherapeuticsMD's Change in Cash history spans 16 years, with the latest figure at $368000.0 for Q4 2025.

  • For Q4 2025, Change in Cash rose 2966.67% year-over-year to $368000.0; the TTM value through Dec 2025 reached $2.4 million, up 231.15%, while the annual FY2025 figure was $2.4 million, 231.15% up from the prior year.
  • Change in Cash reached $368000.0 in Q4 2025 per TXMD's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $57.1 million in Q1 2021 to a low of -$39.7 million in Q4 2021.
  • Average Change in Cash over 5 years is -$3.7 million, with a median of -$87000.0 recorded in 2024.
  • Peak YoY movement for Change in Cash: plummeted 4761.85% in 2021, then surged 6136.36% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$39.7 million in 2021, then soared by 127.66% to $11.0 million in 2022, then plummeted by 153.14% to -$5.8 million in 2023, then surged by 100.21% to $12000.0 in 2024, then surged by 2966.67% to $368000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Change in Cash are $368000.0 (Q4 2025), $1.0 million (Q3 2025), and $324000.0 (Q2 2025).